Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
3 Great Dividend Stocks to Buy in June
11:04am, Sunday, 05'th Jun 2022 The Motley Fool
Investors should be able to count on recurring income with these stocks.
3 Great Dividend Stocks to Buy in June
07:04am, Sunday, 05'th Jun 2022
Investors should be able to count on recurring income with these stocks.
10 Of The Safest Dividend Blue-Chips To Own In A Recession
02:11pm, Wednesday, 01'st Jun 2022 Seeking Alpha
LOW, VFC, ASML, AMAT, MA, CL, NVS, CSCO, V, and NKE are 10 of the safest dividend stocks to own in a recession. Read more about these stocks here.
Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah
04:33pm, Monday, 30'th May 2022
Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.
6 Dividend Stocks With High Yields and Low P/E Ratios
08:00pm, Monday, 23'rd May 2022
6 Dividend stocks with high yields and low P/E ratios. These 6 dividend stocks have yields greater than 2.5% and P/E ratios lower than 16x with a positive earnings growth forecast for 2023.
Three Stock Lunch: JPMorgan, Verizon and Novartis
03:33pm, Thursday, 19'th May 2022
David Wagner, Aptus Capital Advisors portfolio manager, joins 'Power Lunch' to discuss Wagner's take on stocks like JPMorgan, Verizon and Novartis.
Should You Buy This High-Yielding Big Pharma Stock?
10:37am, Wednesday, 18'th May 2022
Novartis can provide investors with a market-crushing 3.8% dividend yield -- and that isn't all the stock has to offer.
Novartis suspends delivery of cancer treatment as it address potential production issues
01:37pm, Thursday, 05'th May 2022
The U.S.-listed shares of Novartis AG NVS, -2.53% NOVN, -0.09% fell 2.6% in afternoon trading Thursday, after the Switzerland-based drug maker said it was "temporarily" suspending delivery of its canc
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?
10:45am, Monday, 02'nd May 2022
CEO Vas Narasimhan is seeking acquisitions under $2 billion.
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN
12:02pm, Thursday, 28'th Apr 2022
Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial
09:47am, Wednesday, 27'th Apr 2022
Novartis AG (NYSE: NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Dat
Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data
06:03am, Wednesday, 27'th Apr 2022
Molecular Partners AG (NASDAQ: MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says
Novartis: Comment On Q1 Results
11:43am, Tuesday, 26'th Apr 2022
Growing quarterly numbers but below market expectations. Withdrawal from Russia manageable.
Novartis AG (NVS) CEO Vasant Narasimhan on Q1 2022 Results - Earnings Call Transcript
10:28am, Tuesday, 26'th Apr 2022
Novartis AG (NYSE:NVS ) Q1 2022 Earnings Conference Call April 26, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vasant Narasimhan - Chief Executive Officer Harry K
Novartis Earnings Get Boost From Sales of Key Drugs
04:36am, Tuesday, 26'th Apr 2022
Sales of heart failure treatment Entresto rise 39% in the first quarter.
